Open AccessLidocaine Attenuates the Development of Diabetic-Induced Tactile Allodynia by Inhibiting Microglial Activation
Author(s) -
Norihiro Suzuki,
Maiko Hasegawa-Moriyama,
Yurika Takahashi,
Yuji Kamikubo,
Takashi Sakurai,
Eiichi Inada
Publication year - 2011
Publication title -
anesthesia and analgesia/anesthesia and analgesia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.404
H-Index - 201
eISSN - 1526-7598
pISSN - 0003-2999
DOI - 10.1213/ane.0b013e31822827a2
Subject(s) - medicine , lidocaine , allodynia , anesthesia , microglia , hyperalgesia , neuroscience , pharmacology , nociception , inflammation , receptor , biology
Lidocaine is used clinically for tactile allodynia associated with diabetes-induced neuropathy. Although the analgesic effect of lidocaine through suppression of microglial activation has been implicated in the development of injury-induced neuropathic pain, its mechanism of action in diabetes-induced tactile allodynia has not yet been completely elucidated.